Eli Lilly (LLY)
(Delayed Data from NYSE)
$807.86 USD
+0.43 (0.05%)
Updated May 28, 2024 04:00 PM ET
Pre-Market: $801.85 -6.01 (-0.74%) 8:22 AM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Brokerage Reports
Eli Lilly and Company [LLY]
Reports for Purchase
Showing records 361 - 380 ( 428 total )
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
CTAD?14: A Renewed Focus Toward the Development of Symptomatic Agents, and our Award for Preclinical ''''One to Watch''''
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: FEIN A
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
The Zyprexa Patent Expiration Has Largely Run Its Course
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S